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What was known?. Migraines affect up to 13% of the population and are significantly more common in women. Up to a third of migraine patients experience aura. A 2004 meta-analysis showed a significant association between ischemic stroke and both migraine with and without aura. 2 What this study adds. This updated meta-analysis incorporates data from six new studies, including three large cohort studies (which increased the sample size from roughly 7800 patients to over 210,000 patients). Only well-designed case-control or cohort studies were included. The investigators found that migraine with aura was associated with a two-fold increase in risk for ischemic stroke (RR =2. 16 , 95%CI, 1.53-3.03). The risk was higher for women than men (RR=2.08, 95%CI, 1.13-3.84), those <45 years (RR=2.65, 95%CI, 1.41-4.97), smokers (RR=9.03, 95%CI, 4. 22-19.34) , and oral contraceptive users (RR = 7.02, 95%CI, 1.51-32.68). Patients with migraine without aura showed no increased risk. There was no association between migraine and myocardial infarction or cardiovascular death.
How should I change my practice?. Aggressive modification of cardiovascular risk factors and alternatives to estrogencontaining contraceptives should be considered for women with migraine with aura.
OVARIAN CANCER SCREENING
Results from Four Rounds of Ovarian Cancer Screening in a Randomized Trial 3 What was known?. Annually in the United States, over 22,000 women are diagnosed with ovarian cancer and over 15,000 die from the disease. Prognosis is greatly improved with diagnosis at an early stage (Stage I or II) compared with later stages. To date, attempts to screen for ovarian cancer using either transvaginal ultrasound or CA125 tumor marker levels have not reduced mortality. 4, 5 What this study adds. This study examined whether screening with both transvaginal ultrasound and CA125 would reduce mortality from ovarian cancer. Over 34,000 women aged 55-74 years were randomized to annual transvaginal ultrasound and CA125 vs. usual care for four years. If either was positive, management was per the patient's personal physician. At the baseline screen, 5.8% of women were positive for either test, 33.8% of whom (n = 566) underwent biopsy, resulting in the diagnosis of 18 What was known?. Combination postmenopausal hormone therapy (PHT) has been associated with a 30% increase in breast cancer risk in the Women's Health Initiative (WHI) Trial. 8 Of women who initiate PHT, up to 25% develop newonset breast tenderness (NOBT), perhaps linked to increased breast cell proliferation. This NOBT has been associated with increased mammographic density, 9 and mammographic density is a risk factor for breast cancer. 10 Thus, it is biologically plausible that NOBT could be associated with breast cancer incidence.
What this study adds. found that the most efficient models initiated screening at age 50 with a biennial interval. Starting screening at age 40 reduced breast cancer mortality by an additional 3% but resulted in more false-positives, whereas biennial screening over the age of 50 retained 81% of the benefit achieved with annual screening. What was known?. Soy foods are rich in isoflavones, which have both estrogen and anti-estrogen effects. 20 Controversy exists regarding the effects of soy consumption on breast cancer risk. 20, 21 What this study adds. This large, prospective cohort study, involving 5,042 breast cancer survivors in Shanghai, assessed the association between soy food intake and total mortality, breast cancer mortality, and breast cancer recurrence. Soy food and isoflavone intake were measured 18 months, 36 months, and 60 months after breast cancer diagnosis and were grouped by quartiles. When comparing the lowest intake quartile to the highest, increasing soy protein intake was associated with a decreased risk for total mortality (adjusted What was known?. Screening bone densitometry is recommended for women aged 65 and over as well as for younger women with risk factors, 25 however whether bone mineral density (BMD) should be monitored once treatment is started is controversial.
26-28
What this study adds. This study was a reanalysis of data from the Fracture Intervention Trial (FIT), 29 in which women were treated with alendronate or placebo, received annual bone densitometry and were followed for fractures. Investigators compared "within-person" variation (measurement) with "between-person" variation (treatment effect) in serial bone density measurements. They found that within-person measurement-related variation was greater than betweenperson treatment-related variation, suggesting that routine monitoring of BMD during the first three years of bisphosphonate treatment is unnecessary. The vast majority of individuals (97.5%) gained bone mineral density with alendronate treatment.
How should I change my practice?. Monitoring BMD in postmenopausal women after starting bisphosphonate treatment for osteoporosis is not necessary. Treatment "failure" is best described by fracture while on therapy rather than a decrease in BMD. What was known?. Spontaneous vertebral fractures can cause significant morbidity and mortality. The use of both vertebroplasty (augmentation of vertebral compression fractures with polymethylmethacrylate (PMAA)) and kyphoplasty (inflating a balloon to restore the vertebral body to its original height while creating a cavity into which PMMA can be injected under low pressure) is increasing despite little evidence to support their use 31 . There have also been reports of procedures being repeated at previously treated levels and the use of prophylactic vertebroplasty at levels deemed to be at high risk for fracture 32, 33 What this study adds. Kyphoplasty was compared to nonsurgical care in 300 participants in 18 countries in participants with acute vertebral fractures of less than 3 months duration. Nonsurgical care included back brace, walking aids, analgesics and physical therapy. At one month follow-up, kyphoplasty recipients had significant improvement in the SF-36 physical component, 5.2 points (95%CI 2.9-7.4) greater than those who received nonsurgical care. At 12 months, there were no differences in outcomes between groups, and subsequent fractures were common in both groups (33% vs 25% control p=NS).
TREATMENT OF OSTEOPOROTIC COMPRESSION FRACTURES
How should I change my practice?. In patients with acute fractures, kyphoplasty improves pain and function at 1 month, with HIV, immunosuppression, DES exposure of history of CIN) Women aged 30 and over who have had at least 3 negative smears can be screened every 3 years (Co-testing with cervical cytology and high risk HPV typing is also appropriate; if co-testing is negative, rescreening can occur in 3 years) Women who have had a hysterectomy do not need cervical cancer screening After age 65-70, screening can cease in women who have had at least 3 previous negative tests and no abnormalities in the past 10 years Those with CIN2, CIN3 or cancer should undergo annual screening for 20 years Breast Cancer Screening USPSTF HPV vaccine does not change these recommendations The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms 51, 52 Screening mammography is recommended every two years for all women aged 50 to 74 There is insufficient evidence to weight the benefits and harms of screening mammography for women older than 75 The evidence for the clinical breast exam is insufficient; women should not be taught how to do breast self-exam ACOG American College of Obstetrics and Gynecology CIN cervical intraepithelial neoplasia HPV human papilloma virus USPSTF United States Preventive Task Force but after 12 months, there was no difference compared with usual care. Kyphoplasty appears to be safe in the short term. Of note, two recent trials showed no benefit of vertebroplasty compared with placebo, although there was a high rate of crossover in the studies; it is possible that the placebo injected into the periosteum may have had some analgesic effect and the participants had fractures that were less acute (<12 months in duration). For individuals with compression fractures who have failed conservative treatment, kyphoplasty may be an option to improve symptoms at one month. Longer term data on efficacy are needed. What this study adds. This prospective cohort study included 1399 nulliparous women, aged 18-30, who had no evidence of metabolic syndrome on blood tests or blood pressure measurements performed at the time of study enrollment. Over twenty years of follow up, 704 women reported one or more singleton births and 120 developed the metabolic syndrome. In analyses controlling for age, race, education, parity, smoking, physical activity, baseline BMI and components of metabolic syndrome, this study found that mothers who did not lactate were at greater risk of developing the metabolic syndrome. These findings were particularly striking for women who had developed gestational diabetes mellitus(GDM); those who lactated for less than 1 month were much more likely to develop the metabolic syndrome (HR =7.14, 1.82-25.00) than mothers who lactated for more than 9 months after a pregnancy affected by GDM. Among mothers who did not lactate incident metabolic syndrome was more common among pregnancies affected by GDM (49.4 per 1000 person-years) than those not affected by GDM (16.7 per 1000 person-years).
LACTATION AND MATERNAL HEALTH
In contrast, among mothers who breastfed for more than 9 months, those with GDM (8.5 per 1000 person years) were not more likely than those without GDM (9.2 per 1000 person years) to develop the metabolic syndrome. What was known?. Levonorgestrel emergency contraception pills (ECP), which are available in the US without a prescription to all individuals over the age of 17 as Plan B one step or the generic, Next Choice, are at least twice as effective as the Yuzpe regimen. 47, 48 However, as unintended pregnancy and abortion remain common, 49 the search for better contraceptives continues.
What this study adds. This randomized, blinded, controlled trial, which enrolled 2221 women from 35 clinics in the United Kingdom, Ireland, and the USA, was designed to show that 30 mg of ulipristal acetate is non-inferior to 1.5 mg of levonorgestrel when used as EC within 5 days of unprotected intercourse. Adverse events were similar between groups and included headache (19%), dysmenorrhea (14%), and nausea (12%). Pregnancy rates with use of either ECP (1.8% with ulipristal acetate vs 2.6% with levonorgestrel) were lower than the 5.5 % expected without use of ECP. In a meta-analysis which combined the results of this study with a similar study, 50 the investigators reported that women using ulipristal acetate for EC were less likely than women using levonorgestrel within 5 days of unprotected sex to become pregnant (OR=0.55, 95%CI 0.32-0.93).
How should this change my practice?. Ulipristal acetate has recently been approved for EC use in Europe and the US (as "ella"). Advance prescription of ulipristal acetate should be considered for all patients using barrier methods of contraception.
